FDA To Adopt Cost-Effectiveness Role? Congress May Revisit Issue, Crawford Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Medicare reform will link FDA more closely with CMS, which could necessitate FDA becoming more economically aware of approval decisions, Acting Commissioner Crawford says. FDAer envisions a relationship with CMS that is akin to a merger.
You may also be interested in...
FDA Mission Should Not Include Rx Cost Effectiveness, Rep. Allen Says
Comparative studies should be "untainted" by industry's influence, the Maine Democrat says. He urges full appropriation of funding to AHRQ under the new Medicare law.
FDA Mission Should Not Include Rx Cost Effectiveness, Rep. Allen Says
Comparative studies should be "untainted" by industry's influence, the Maine Democrat says. He urges full appropriation of funding to AHRQ under the new Medicare law.
Rx Cost-Effectiveness Research Is Government's Job, But Not FDA's, AMCP Says
AHRQ and NIH have role in carrying out post-approval drug research, but FDA's authority is limited to approving drugs based on safety and efficacy, Academy of Managed Care Pharmacy policy statement says.